BiotechTube

Binimetinib

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type 1

Conditions

Neurofibromatosis Type 1, Plexiform Neurofibroma

Trial Timeline

Nov 28, 2017 → Apr 17, 2024

NCT ID
NCT03231306

About Binimetinib

Binimetinib is a phase 2 stage product being developed by Pacific Biosciences for Neurofibromatosis Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT03231306. Target conditions include Neurofibromatosis Type 1, Plexiform Neurofibroma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03231306Phase 2Completed

Competing Products

20 competing products in Neurofibromatosis Type 1

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
52
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
33
AZD2014AstraZenecaPhase 2
52
Selumetinib + PlaceboAstraZenecaPhase 2
52
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
41
SelumetinibAstraZenecaPhase 3
77
Everolimus (RAD001) , Afinitor®NovartisPhase 2
52
RAD001: EverolimusNovartisPhase 2
52
RAD001, everolimusNovartisPhase 2
52
TasignaNovartisPhase 1
33
TrametinibNovartisPhase 2
52
Everolimus (RAD001)NovartisPhase 2
52
Sutent®/SunitinibPfizerPhase 2
51
Sorafenib (Nexavar)BayerPhase 2
49
PTC299United TherapeuticsPhase 2
49
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
60

Other Products from Pacific Biosciences

pantoprazole + bismuth + metronidazole + tetracyclineApproved
77
EmtricitabineApproved
77
A single oral 5 mg of duterium labeled methamphetamineApproved
77
RamiprilApproved
77
Emtricitabine plus adefovir dipivoxilApproved
77